;PMID: 8328780
;source_file_636.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..52] = [t:0..52]
;1)sentence:[e:58..196] = [t:58..196]
;2)section:[e:200..248] = [t:200..248]
;3)section:[e:252..335] = [t:252..335]
;4)sentence:[e:339..501] = [t:339..501]
;5)sentence:[e:502..693] = [t:502..693]
;6)sentence:[e:694..878] = [t:694..878]
;7)sentence:[e:880..1057] = [t:880..1057]
;8)sentence:[e:1058..1323] = [t:1058..1323]
;9)sentence:[e:1324..1587] = [t:1324..1587]
;10)sentence:[e:1589..1719] = [t:1589..1719]
;11)sentence:[e:1720..1926] = [t:1720..1926]
;12)sentence:[e:1927..2042] = [t:1927..2042]
;13)sentence:[e:2043..2203] = [t:2043..2203]
;14)sentence:[e:2204..2317] = [t:2204..2317]
;15)sentence:[e:2318..2575] = [t:2318..2575]
;16)sentence:[e:2576..2756] = [t:2576..2756]
;17)section:[e:2760..2804] = [t:2760..2804]

;section 0 Span:0..52
;Antimicrob Agents Chemother. 1993 Jun;37(6):1318-23.
(SEC
  (FRAG (NNP:[0..10] Antimicrob) (NNPS:[11..17] Agents) (NNP:[18..27] Chemother)
        (.:[27..28] .) (CD:[29..33] 1993) (CC:[34..39] Jun;3) (CD:[39..40] 7)
        (NN:[40..41] -LRB-) (NN:[41..42] 6) (NN:[42..43] -RRB-) (::[43..44] :)
        (CD:[44..47] 131) (CD:[47..51] 8-23) (.:[51..52] .)))

;sentence 1 Span:58..196
;Enhancement of drug susceptibility in Plasmodium falciparum in vitro and 
;Plasmodium berghei in vivo by mixed-function oxidase inhibitors.
;[73..77]:substance:"drug"
;[162..184]:substance:"mixed-function oxidase"
;[185..195]:substance:"inhibitors"
(SENT
  (NP-HLN
    (NP (NN:[58..69] Enhancement))
    (PP (IN:[70..72] of)
      (NP (NN:[73..77] drug) (NN:[78..92] susceptibility)))
    (PP-LOC (IN:[93..95] in)
      (NP
        (NP
          (NP (NNP:[96..106] Plasmodium) (NNP:[107..117] falciparum))
          (ADJP (FW:[118..120] in) (FW:[121..126] vitro)))
        (CC:[127..130] and)
        (NP
          (NP (NNP:[132..142] Plasmodium) (NNP:[143..150] berghei))
          (ADJP (FW:[151..153] in) (FW:[154..158] vivo)))))
    (PP (IN:[159..161] by)
      (NP
        
        (NML (JJ:[162..167] mixed) (HYPH:[167..168] -) (NN:[168..176] function))
        (NN:[177..184] oxidase)
        (NNS:[185..195] inhibitors)))
    (.:[195..196] .)))

;section 2 Span:200..248
;Ndifor AM, Howells RE, Bray PG, Ngu JL, Ward SA.
(SEC
  (FRAG (VBG:[200..206] Ndifor) (NNP:[207..209] AM) (,:[209..210] ,)
        (NNP:[211..218] Howells) (NNP:[219..221] RE) (,:[221..222] ,)
        (NNP:[223..227] Bray) (NNP:[228..230] PG) (,:[230..231] ,)
        (NNP:[232..235] Ngu) (NNP:[236..238] JL) (,:[238..239] ,)
        (NNP:[240..244] Ward) (NNP:[245..247] SA) (.:[247..248] .)))

;section 3 Span:252..335
;Department of Parasitology, Liverpool School of Tropical Medicine, United 
;Kingdom.
(SEC
  (FRAG (NNP:[252..262] Department) (IN:[263..265] of)
        (NNP:[266..278] Parasitology) (,:[278..279] ,)
        (NNP:[280..289] Liverpool) (NNP:[290..296] School) (IN:[297..299] of)
        (NNP:[300..308] Tropical) (NNP:[309..317] Medicine) (,:[317..318] ,)
        (NNP:[319..325] United) (NNP:[327..334] Kingdom) (.:[334..335] .)))

;sentence 4 Span:339..501
;A number of compounds, as exemplified by verapamil and desipramine, have been
; shown to enhance the susceptibility of resistant malaria parasites to 
;chloroquine.
;[351..360]:substance:"compounds"
;[380..389]:substance:"verapamil"
;[394..405]:substance:"desipramine"
;[489..500]:substance:"chloroquine"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[339..340] A) (NN:[341..347] number))
      (PP (IN:[348..350] of)
        (NP (NNS:[351..360] compounds)))
      (,:[360..361] ,)
      (PP (IN:[362..364] as)
        (S-NOM
          (NP-SBJ-2 (-NONE-:[364..364] *))
          (VP (VBN:[365..376] exemplified)
            (NP-2 (-NONE-:[376..376] *))
            (PP (IN:[377..379] by)
              (NP (NN:[380..389] verapamil) (CC:[390..393] and)
                  (NN:[394..405] desipramine)))))))
    (,:[405..406] ,)
    (VP (VBP:[407..411] have)
      (VP (VBN:[412..416] been)
        (VP (VBN:[418..423] shown)
          (S
            (NP-SBJ-1 (-NONE-:[423..423] *))
            (VP (TO:[424..426] to)
              (VP (VB:[427..434] enhance)
                (NP
                  (NP (DT:[435..438] the) (NN:[439..453] susceptibility))
                  (PP (IN:[454..456] of)
                    (NP (JJ:[457..466] resistant) (NN:[467..474] malaria)
                        (NNS:[475..484] parasites)))
                  (PP (TO:[485..487] to)
                    (NP (NN:[489..500] chloroquine))))))))))
    (.:[500..501] .)))

;sentence 5 Span:502..693
;The mechanism by which these agents reverse resistance is still 
;controversial but is though to involve alterations in drug transport causing
;an  increase in steady-state drug concentrations.
;[531..537]:substance:"agents"
;[621..625]:substance:"drug"
;[673..677]:substance:"drug"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[502..505] The) (NN:[506..515] mechanism))
      (SBAR
        (WHPP-1 (IN:[516..518] by)
          (WHNP (WDT:[519..524] which)))
        (S
          (NP-SBJ (DT:[525..530] these) (NNS:[531..537] agents))
          (VP (VBP:[538..545] reverse)
            (NP (NN:[546..556] resistance))
            (PP-1 (-NONE-:[556..556] *T*))))))
    (VP
      (VP (VBZ:[557..559] is)
        (ADVP-TMP (RB:[560..565] still))
        (ADJP-PRD (JJ:[567..580] controversial)))
      (CC:[581..584] but)
      (VP (VBZ:[585..587] is)
        (VP (RB:[588..594] though)
          (S
            (NP-SBJ-2 (-NONE-:[594..594] *))
            (VP (TO:[595..597] to)
              (VP (VB:[598..605] involve)
                (NP
                  (NP
                    (NP (NNS:[606..617] alterations))
                    (PP (IN:[618..620] in)
                      (NP (NN:[621..625] drug) (NN:[626..635] transport))))
                  (VP (VBG:[636..643] causing)
                    (NP
                      (NP (DT:[644..646] an) (NN:[648..656] increase))
                      (PP (IN:[657..659] in)
                        (NP
                          (NML (JJ:[660..666] steady) (HYPH:[666..667] -)
                               (NN:[667..672] state))
                          (NN:[673..677] drug) (NNS:[678..692] concentrations))))))))))))
    (.:[692..693] .)))

;sentence 6 Span:694..878
;We have proposed that an  alternative resistance mechanism may involve the
;metabolic deactivation of the  drug in some resistant parasites via
;cytochrome P-450 mixed-function oxidases.
;[800..804]:substance:"drug"
;[837..853]:cyp450:"cytochrome P-450"
;[854..877]:substance:"mixed-function oxidases"
(SENT
  (S
    (NP-SBJ (PRP:[694..696] We))
    (VP (VBP:[697..701] have)
      (VP (VBN:[702..710] proposed)
        (SBAR (IN:[711..715] that)
          (S
            (NP-SBJ (DT:[716..718] an) (JJ:[720..731] alternative)
                    (NN:[732..742] resistance) (NN:[743..752] mechanism))
            (VP (MD:[753..756] may)
              (VP (VB:[757..764] involve)
                (NP
                  (NP (DT:[765..768] the) (JJ:[769..778] metabolic)
                      (NN:[779..791] deactivation))
                  (PP (IN:[792..794] of)
                    (NP (DT:[795..798] the) (NN:[800..804] drug)))
                  (PP-LOC (IN:[805..807] in)
                    (NP (DT:[808..812] some) (JJ:[813..822] resistant)
                        (NNS:[823..832] parasites)))
                  (PP (IN:[833..836] via)
                    (NP
                      (NML (NN:[837..847] cytochrome) (NN:[848..853] P-450))
                      
                      (NML (JJ:[854..859] mixed) (HYPH:[859..860] -)
                           (NN:[860..868] function))
                      (NNS:[869..877] oxidases))))))))))
    (.:[877..878] .)))

;sentence 7 Span:880..1057
;If the hypothesis is true, it should be possible to alter drug susceptibility
;in  malaria parasites by the use of agents known to inhibit or induce
;cytochrome  P-450 activities.
;[938..942]:substance:"drug"
;[994..1000]:substance:"agents"
;[1028..1045]:cyp450:"cytochrome  P-450"
(SENT
  (S
    (SBAR-ADV (IN:[880..882] If)
      (S
        (NP-SBJ (DT:[883..886] the) (NN:[887..897] hypothesis))
        (VP (VBZ:[898..900] is)
          (ADJP-PRD (JJ:[901..905] true)))))
    (,:[905..906] ,)
    (NP-SBJ (PRP:[907..909] it))
    (VP (MD:[910..916] should)
      (VP (VB:[917..919] be)
        (ADJP-PRD (JJ:[920..928] possible)
          (S
            (NP-SBJ (-NONE-:[928..928] *))
            (VP (TO:[929..931] to)
              (VP (VB:[932..937] alter)
                (NP (NN:[938..942] drug) (NN:[943..957] susceptibility))
                (PP-LOC (IN:[958..960] in)
                  (NP (NN:[962..969] malaria) (NNS:[970..979] parasites)))
                (PP-MNR (IN:[980..982] by)
                  (NP
                    (NP (DT:[983..986] the) (NN:[987..990] use))
                    (PP (IN:[991..993] of)
                      (NP
                        (NP (NNS:[994..1000] agents))
                        (VP (JJ:[1001..1006] known)
                          (S
                            (NP-SBJ (-NONE-:[1006..1006] *))
                            (VP (TO:[1007..1009] to)
                              (VP (VB:[1010..1017] inhibit) (CC:[1018..1020] or)
                                  (VB:[1021..1027] induce)
                                (NP
                                  (NML (NN:[1028..1038] cytochrome)
                                       (NN:[1040..1045] P-450))
                                  (NNS:[1046..1056] activities))))))))))))))))
    (.:[1056..1057] .)))

;sentence 8 Span:1058..1323
;We have assessed the ability of known inhibitors of cytochrome  P-450 enzymes
;(cimetidine, metyrapone, and alpha-naphthoflavone) to enhance  chloroquine
;susceptibility in Plasmodium falciparum culture-adapted and  wild-type
;isolates in vitro and P. berghei in vivo.
;[1096..1106]:substance:"inhibitors"
;[1110..1135]:cyp450:"cytochrome  P-450 enzymes"
;[1137..1147]:substance:"cimetidine"
;[1149..1159]:substance:"metyrapone"
;[1165..1185]:substance:"alpha-naphthoflavone"
;[1199..1210]:substance:"chloroquine"
(SENT
  (S
    (NP-SBJ (PRP:[1058..1060] We))
    (VP (VBP:[1061..1065] have)
      (VP (VBN:[1066..1074] assessed)
        (NP
          (NP (DT:[1075..1078] the) (NN:[1079..1086] ability)
            (S-3 (-NONE-:[1086..1086] *ICH*)))
          (PP (IN:[1087..1089] of)
            (NP
              (NP
                (NP (JJ:[1090..1095] known) (NNS:[1096..1106] inhibitors))
                (PP (IN:[1107..1109] of)
                  (NP
                    (NML (NN:[1110..1120] cytochrome) (NN:[1122..1127] P-450))
                    (NNS:[1128..1135] enzymes))))
              (PRN (-LRB-:[1136..1137] -LRB-)
                (NP (NN:[1137..1147] cimetidine) (,:[1147..1148] ,)
                    (NN:[1149..1159] metyrapone) (,:[1159..1160] ,)
                    (CC:[1161..1164] and) (NN:[1165..1185] alpha-naphthoflavone))
                (-RRB-:[1185..1186] -RRB-))))
          (S-3
            (NP-SBJ (-NONE-:[1186..1186] *))
            (VP (TO:[1187..1189] to)
              (VP
                (VP (VB:[1190..1197] enhance)
                  (NP (NN:[1199..1210] chloroquine)
                      (NN:[1211..1225] susceptibility))
                  (PP-LOC (IN:[1226..1228] in)
                    (NP=4
                      (NP
                        (NML-2 (NNP:[1229..1239] Plasmodium)
                               (NNP:[1240..1250] falciparum))
                        (ADJP (NN:[1251..1258] culture) (HYPH:[1258..1259] -)
                              (VBN:[1259..1266] adapted))
                        (NML-1 (-NONE-:[1266..1266] *P*)))
                      (CC:[1267..1270] and)
                      (NP
                        (NML-2 (-NONE-:[1270..1270] *P*))
                        (ADJP (JJ:[1272..1276] wild) (HYPH:[1276..1277] -)
                              (NN:[1277..1281] type))
                        (NML-1 (NNS:[1282..1290] isolates)))))
                  (ADVP=5 (FW:[1291..1293] in) (FW:[1294..1299] vitro)))
                (CC:[1300..1303] and)
                (VP
                  (NP=4 (NNP:[1304..1306] P.) (NNP:[1307..1314] berghei))
                  (ADVP=5 (FW:[1315..1317] in) (FW:[1318..1322] vivo)))))))))
    (.:[1322..1323] .)))

;sentence 9 Span:1324..1587
;In all three systems, the  inhibitor cimetidine enhanced parasite
;susceptibility to chloroquine, and this  increase in susceptibility was
;unrelated to changes in chloroquine steady-state  concentrations in vitro or
;to alterations in host pharmacokinetics in vivo.
;[1351..1360]:substance:"inhibitor"
;[1361..1371]:substance:"cimetidine"
;[1408..1419]:substance:"chloroquine"
;[1486..1497]:substance:"chloroquine"
(SENT
  (S
    (S
      (PP-LOC (IN:[1324..1326] In)
        (NP (DT:[1327..1330] all) (CD:[1331..1336] three)
            (NNS:[1337..1344] systems)))
      (,:[1344..1345] ,)
      (NP-SBJ
        (NP (DT:[1346..1349] the) (NN:[1351..1360] inhibitor))
        (NP (NN:[1361..1371] cimetidine)))
      (VP (VBD:[1372..1380] enhanced)
        (NP (NN:[1381..1389] parasite) (NN:[1390..1404] susceptibility))
        (PP (TO:[1405..1407] to)
          (NP (NN:[1408..1419] chloroquine)))))
    (,:[1419..1420] ,) (CC:[1421..1424] and)
    (S
      (NP-SBJ
        (NP (DT:[1425..1429] this) (NN:[1431..1439] increase))
        (PP (IN:[1440..1442] in)
          (NP (NN:[1443..1457] susceptibility))))
      (VP (VBD:[1458..1461] was)
        (ADJP-PRD (JJ:[1462..1471] unrelated)
          (PP
            (PP (TO:[1472..1474] to)
              (NP
                (NP (NNS:[1475..1482] changes))
                (PP-LOC (IN:[1483..1485] in)
                  (NP (NN:[1486..1497] chloroquine)
                    (NML (JJ:[1498..1504] steady) (HYPH:[1504..1505] -)
                         (NN:[1505..1510] state))
                    (NNS:[1512..1526] concentrations)))
                (ADJP (FW:[1527..1529] in) (FW:[1530..1535] vitro))))
            (CC:[1536..1538] or)
            (PP (TO:[1539..1541] to)
              (NP
                (NP (NNS:[1542..1553] alterations))
                (PP-LOC (IN:[1554..1556] in)
                  (NP (NN:[1557..1561] host) (NNS:[1562..1578] pharmacokinetics)))
                (ADJP (FW:[1579..1581] in) (FW:[1582..1586] vivo))))))))
    (.:[1586..1587] .)))

;sentence 10 Span:1589..1719
;Additionally, the cytochrome P-450 inducer phenobarbital produced slight 
;decreases in P. falciparum drug susceptibility in vitro.
;[1607..1623]:cyp450:"cytochrome P-450"
;[1624..1631]:substance:"inducer"
;[1632..1645]:substance:"phenobarbital"
;[1690..1694]:substance:"drug"
(SENT
  (S
    (ADVP (RB:[1589..1601] Additionally))
    (,:[1601..1602] ,)
    (NP-SBJ
      (NP (DT:[1603..1606] the)
        (NML (NN:[1607..1617] cytochrome) (NN:[1618..1623] P-450))
        (NN:[1624..1631] inducer))
      (NP (NN:[1632..1645] phenobarbital)))
    (VP (VBD:[1646..1654] produced)
      (NP
        (NP (JJ:[1655..1661] slight) (NNS:[1663..1672] decreases))
        (PP (IN:[1673..1675] in)
          (NP
            (NML (NNP:[1676..1678] P.) (NNP:[1679..1689] falciparum))
            (NN:[1690..1694] drug) (NN:[1695..1709] susceptibility))))
      (ADVP (FW:[1710..1712] in) (FW:[1713..1718] vitro)))
    (.:[1718..1719] .)))

;sentence 11 Span:1720..1926
;We have compared the  ability of the cytochrome P-450 inhibitors cimetidine
;and metyrapone to enhance  drug susceptibility with that of verapamil by
;using wild-type malaria isolates  obtained from Cameroon.
;[1757..1773]:cyp450:"cytochrome P-450"
;[1774..1784]:substance:"inhibitors"
;[1785..1795]:substance:"cimetidine"
;[1800..1810]:substance:"metyrapone"
;[1823..1827]:substance:"drug"
;[1856..1865]:substance:"verapamil"
(SENT
  (S
    (NP-SBJ (PRP:[1720..1722] We))
    (VP (VBP:[1723..1727] have)
      (VP (VBN:[1728..1736] compared)
        (NP
          (NP (DT:[1737..1740] the) (NN:[1742..1749] ability)
            (S-PRP-1 (-NONE-:[1749..1749] *ICH*)))
          (PP (IN:[1750..1752] of)
            (NP
              (NP (DT:[1753..1756] the)
                (NML (NN:[1757..1767] cytochrome) (NN:[1768..1773] P-450))
                (NNS:[1774..1784] inhibitors))
              (NP (NN:[1785..1795] cimetidine) (CC:[1796..1799] and)
                  (NN:[1800..1810] metyrapone))))
          (S-PRP-1
            (NP-SBJ (-NONE-:[1810..1810] *))
            (VP (TO:[1811..1813] to)
              (VP (VB:[1814..1821] enhance)
                (NP (NN:[1823..1827] drug) (NN:[1828..1842] susceptibility))))))
        (PP (IN:[1843..1847] with)
          (NP
            (NP (DT:[1848..1852] that))
            (PP (IN:[1853..1855] of)
              (NP (NN:[1856..1865] verapamil)))))
        (PP (IN:[1866..1868] by)
          (S-NOM
            (NP-SBJ (-NONE-:[1868..1868] *))
            (VP (VBG:[1869..1874] using)
              (NP
                (NP
                  (NML (JJ:[1875..1879] wild) (HYPH:[1879..1880] -)
                       (NN:[1880..1884] type))
                  (NN:[1885..1892] malaria) (NNS:[1893..1901] isolates))
                (VP (VBN:[1903..1911] obtained)
                  (NP (-NONE-:[1911..1911] *))
                  (PP (IN:[1912..1916] from)
                    (NP (NNP:[1917..1925] Cameroon))))))))))
    (.:[1925..1926] .)))

;sentence 12 Span:1927..2042
;Verapamil completely reversed resistance, i.e., to below  the cutoff point of
;70 nM, in all the resistant isolates.
;[1927..1936]:substance:"Verapamil"
;[2005..2007]:quantitative-value:"70"
;[2008..2010]:quantitative-units:"nM"
(SENT
  (S
    (NP-SBJ (NN:[1927..1936] Verapamil))
    (VP
      (ADVP (RB:[1937..1947] completely))
      (VBD:[1948..1956] reversed)
      (NP (NN:[1957..1967] resistance))
      (,:[1967..1968] ,)
      (ADVP (FW:[1969..1973] i.e.) (,:[1973..1974] ,)
        (PP (TO:[1975..1977] to)
          (PP (IN:[1978..1983] below)
            (NP
              (NP (DT:[1985..1988] the) (NN:[1989..1995] cutoff)
                  (NN:[1996..2001] point))
              (PP (IN:[2002..2004] of)
                (NP (CD:[2005..2007] 70) (NN:[2008..2010] nM)))))))
      (,:[2010..2011] ,)
      (PP-LOC (IN:[2012..2014] in)
        (NP (PDT:[2015..2018] all) (DT:[2019..2022] the)
            (JJ:[2023..2032] resistant) (NNS:[2033..2041] isolates))))
    (.:[2041..2042] .)))

;sentence 13 Span:2043..2203
;Cimetidine enhanced  chloroquine susceptibility in 60% of the isolates and
;reduced 50% inhibitory  concentrations by at least 43% in all the resistant
;isolates.
;[2043..2053]:substance:"Cimetidine"
;[2064..2075]:substance:"chloroquine"
;[2094..2097]:quantitative-value:"60%"
;[2126..2129]:quantitative-value:"50%"
;[2160..2172]:quantitative-value:"at least 43%"
(SENT
  (S
    (NP-SBJ (NN:[2043..2053] Cimetidine))
    (VP
      (VP (VBD:[2054..2062] enhanced)
        (NP (NN:[2064..2075] chloroquine) (NN:[2076..2090] susceptibility))
        (PP-LOC (IN:[2091..2093] in)
          (NP
            (NP (CD:[2094..2096] 60) (NN:[2096..2097] %))
            (PP (IN:[2098..2100] of)
              (NP (DT:[2101..2104] the) (NNS:[2105..2113] isolates))))))
      (CC:[2114..2117] and)
      (VP (VBD:[2118..2125] reduced)
        (NP
          (NML (CD:[2126..2128] 50) (NN:[2128..2129] %))
          (JJ:[2130..2140] inhibitory) (NNS:[2142..2156] concentrations))
        (PP-EXT (IN:[2157..2159] by)
          (NP
            (QP (IN:[2160..2162] at) (JJS:[2163..2168] least)
                (CD:[2169..2171] 43))
            (NN:[2171..2172] %)))
        (PP-LOC (IN:[2173..2175] in)
          (NP (PDT:[2176..2179] all) (DT:[2180..2183] the)
              (JJ:[2184..2193] resistant) (NNS:[2194..2202] isolates)))))
    (.:[2202..2203] .)))

;sentence 14 Span:2204..2317
;The compounds  tested had little or no effect on the 50% inhibitory
;concentrations for the  susceptible isolates.
;[2208..2217]:substance:"compounds"
;[2257..2260]:quantitative-value:"50%"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[2204..2207] The) (NNS:[2208..2217] compounds))
      (VP (VBN:[2219..2225] tested)
        (NP (-NONE-:[2225..2225] *))))
    (VP (VBD:[2226..2229] had)
      (NP
        (NP
          (NP (JJ:[2230..2236] little)
            (NML-1 (-NONE-:[2236..2236] *P*)))
          (CC:[2237..2239] or)
          (NP (DT:[2240..2242] no)
            (NML-1 (NN:[2243..2249] effect))))
        (PP (IN:[2250..2252] on)
          (NP (DT:[2253..2256] the)
            (NML (CD:[2257..2259] 50) (NN:[2259..2260] %))
            (JJ:[2261..2271] inhibitory) (NNS:[2272..2286] concentrations))))
      (PP (IN:[2287..2290] for)
        (NP (DT:[2291..2294] the) (JJ:[2296..2307] susceptible)
            (NNS:[2308..2316] isolates))))
    (.:[2316..2317] .)))

;sentence 15 Span:2318..2575
;The data support a possible role for detoxification in  chloroquine
;resistance, and even in the absence of such a process we have  observed
;apparent chemosensitization by agents whose common biological feature  is the
;inhibition of cytochrome P-450 enzymes.
;[2374..2385]:substance:"chloroquine"
;[2489..2495]:substance:"agents"
;[2550..2574]:cyp450:"cytochrome P-450 enzymes"
(SENT
  (S
    (S
      (NP-SBJ (DT:[2318..2321] The) (NNS:[2322..2326] data))
      (VP (VBP:[2327..2334] support)
        (NP
          (NP (DT:[2335..2336] a) (JJ:[2337..2345] possible)
              (NN:[2346..2350] role))
          (PP (IN:[2351..2354] for)
            (NP (NN:[2355..2369] detoxification)))
          (PP (IN:[2370..2372] in)
            (NP (NN:[2374..2385] chloroquine) (NN:[2386..2396] resistance))))))
    (,:[2396..2397] ,) (CC:[2398..2401] and)
    (S
      (PP (RB:[2402..2406] even) (IN:[2407..2409] in)
        (NP
          (NP (DT:[2410..2413] the) (NN:[2414..2421] absence))
          (PP (IN:[2422..2424] of)
            (NP (JJ:[2425..2429] such) (DT:[2430..2431] a)
                (NN:[2432..2439] process)))))
      (NP-SBJ (PRP:[2440..2442] we))
      (VP (VBP:[2443..2447] have)
        (VP (VBN:[2449..2457] observed)
          (NP
            (NP (JJ:[2458..2466] apparent) (NN:[2467..2485] chemosensitization))
            (PP (IN:[2486..2488] by)
              (NP
                (NP (NNS:[2489..2495] agents))
                (SBAR
                  (WHNP-1 (WP$:[2496..2501] whose))
                  (S
                    (NP-SBJ
                      (NP-1 (-NONE-:[2501..2501] *T*))
                      (JJ:[2502..2508] common) (JJ:[2509..2519] biological)
                       (NN:[2520..2527] feature))
                    (VP (VBZ:[2529..2531] is)
                      (NP-PRD
                        (NP (DT:[2532..2535] the) (NN:[2536..2546] inhibition))
                        (PP (IN:[2547..2549] of)
                          (NP
                            (NML (NN:[2550..2560] cytochrome)
                                 (NN:[2561..2566] P-450))
                            (NNS:[2567..2574] enzymes)))))))))))))
    (.:[2574..2575] .)))

;sentence 16 Span:2576..2756
;Additionally, sensitization has  been observed in wild-type isolates of P.
;falciparum obtained form immune  residents of an area of endemicity as well
;as culture-adapted parasites.
(SENT
  (S
    (ADVP (RB:[2576..2588] Additionally))
    (,:[2588..2589] ,)
    (NP-SBJ-1 (NN:[2590..2603] sensitization))
    (VP (VBZ:[2604..2607] has)
      (VP (VBN:[2609..2613] been)
        (VP (VBN:[2614..2622] observed)
          (NP-1 (-NONE-:[2622..2622] *))
          (PP-LOC (IN:[2623..2625] in)
            (NP
              (NP
                (NP
                  (NP
                    (NML (JJ:[2626..2630] wild) (HYPH:[2630..2631] -)
                         (NN:[2631..2635] type))
                    (NNS:[2636..2644] isolates))
                  (PP (IN:[2645..2647] of)
                    (NP (NNP:[2648..2650] P.) (NNP:[2651..2661] falciparum))))
                (VP (VBN:[2662..2670] obtained)
                  (NP (-NONE-:[2670..2670] *))
                  (PP (NN:[2671..2675] form)
                    (NP
                      (NP (JJ:[2676..2682] immune) (NNS:[2684..2693] residents))
                      (PP (IN:[2694..2696] of)
                        (NP
                          (NP (DT:[2697..2699] an) (NN:[2700..2704] area))
                          (PP (IN:[2705..2707] of)
                            (NP (NN:[2708..2718] endemicity)))))))))
              (CONJP (RB:[2719..2721] as) (RB:[2722..2726] well)
                     (IN:[2727..2729] as))
              (NP
                (ADJP (NN:[2730..2737] culture) (HYPH:[2737..2738] -)
                      (VBN:[2738..2745] adapted))
                (NNS:[2746..2755] parasites)))))))
    (.:[2755..2756] .)))

;section 17 Span:2760..2804
;PMID: 8328780 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2760..2764] PMID) (::[2764..2765] :) (CD:[2766..2773] 8328780)
        (NN:[2774..2775] -LSB-) (NNP:[2775..2781] PubMed) (::[2782..2783] -)
        (NN:[2784..2791] indexed) (IN:[2792..2795] for)
        (NNP:[2796..2804] MEDLINE-RSB-)))
